Carcinogenesis, Vol 19, 509-514, Copyright © 1998 by Oxford University Press
P Lazarus, SN Sheikh, Q Ren, SP Schantz, JC Stern, JP Richie Jr and JY Park
Inactivation of tumor suppressor genes like p53 and p16 play a key role in
tumor progression, with a high incidence of mutations existing for both
genes in oral squamous cell carcinomas. Previous studies have demonstrated,
(i) a correlation between the prevalence of p53 mutations and tobacco use
[Brennan et al. (1995) New Engl. J. Med., 332, 712-717; Lazarus et al.
(1996) Carcinogenesis, 17, 733-739], and (ii) a link between genotypes in
specific xenobiotic metabolizing enzymes and oral cancer susceptibility
[Park et al. (1997) Cancer Epid. Biomarkers Prev., 6, 791-797). In this
paper, we present results of our examination of a series of 80 oral
squamous cell carcinomas for p53 exons 5-9 and p16 exons 1-2 mutations, and
the potential association of these mutations with specific genotyping
patterns. p53 mutation prevalence in oral tumors was linked with increased
patient tobacco use using several stratification criteria. There was a
significantly higher prevalence of p53 mutations in OCSCCs from patients
who smoked > 30 pack-years as compared to tumors from patients who
smoked < or = 30 pack-years (OR = 2.8; CI = 1.1-7.2). No significant
association was observed with patient alcohol consumption. There was a
significant association between the prevalence of p53 mutations in oral
tumors and CYP1A1 genotyping patterns in these oral cancer patients, with
the highest p53 mutation prevalence observed in subjects with the CYP1A1
[val]/GSTM1 [+] genotype (OR = 6.0; CI = 1.2-29.7). A significant
association was not observed between the prevalence of p16 mutations in
oral tumors and tobacco use, or CYP1A1 [val] or GSTM1 (0/0) genotypes.
These data suggest that the induction of mutations in specific tumor
suppressor genes or oncogenes in oral tumors may be associated with
specific carcinogen exposures, and that this association may be linked to
specific polymorphic genotypes in xenobiotic-metabolizing enzyme genes.
ARTICLES
p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use
Department of Pathology and Laboratory Medicine, Temple University, School of Medicine, Philadelphia, PA 19140, USA. plazarus@vm.temple.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. M. Applebaum, C. S. Furniss, A. Zeka, M. R. Posner, J. F. Smith, J. Bryan, E. A. Eisen, E. S. Peters, M. D. McClean, and K. T. Kelsey Lack of Association of Alcohol and Tobacco with HPV16-Associated Head and Neck Cancer J Natl Cancer Inst, December 5, 2007; 99(23): 1801 - 1810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Montero, L. Serrano, A. Araujo, V. Davila, J. Ponce, R. Camacho, E. Morales, and A. Mendez Increased cytogenetic damage in a zone in transition from agricultural to industrial use: comprehensive analysis of the micronucleus test in peripheral blood lymphocytes Mutagenesis, September 1, 2006; 21(5): 335 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ali, B. F. El-Rayes, L. K. Heilbrun, F. H. Sarkar, J. F. Ensley, O. Kucuk, and P. A. Philip Cytochrome P450 and Glutathione Transferase Expression in Squamous Cell Cancer Clin. Cancer Res., July 1, 2004; 10(13): 4412 - 4416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Shields Tobacco Smoking, Harm Reduction, and Biomarkers J Natl Cancer Inst, October 2, 2002; 94(19): 1435 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-L. Hsieh, P.-F. Wang, I.-H. Chen, C.-T. Liao, H.-M. Wang, M.-C. Chen, J. T.-C. Chang, and A.-J. Cheng Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese Carcinogenesis, September 1, 2001; 22(9): 1497 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. Vahakangas, W. P. Bennett, K. Castren, J. A. Welsh, M. A. Khan, B. Blomeke, M. C. R. Alavanja, and C. C. Harris p53 and K-ras Mutations in Lung Cancers from Former and Never-Smoking Women Cancer Res., June 1, 2001; 61(11): 4350 - 4356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Song, W. Tan, D. Xing, and D. Lin CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China Carcinogenesis, January 1, 2001; 22(1): 11 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28. [Abstract] [Full Text]
|
|
|
|
|
|
M. Sato, T. Sato, T. Izumo, and T. Amagasa Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer Carcinogenesis, October 1, 1999; 20(10): 1927 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Matthias, V. Jahnke, P. W. Jones, P. R. Hoban, J. E. Alldersea, S. F. Worrall, A. A. Fryer, and R. C. Strange Cyclin D1, Glutathione S-Transferase, and Cytochrome P450 Genotypes and Outcome in Patients with Upper Aerodigestive Tract Cancers: Assessment of the Importance of Individual Genes Using Multivariate Analysis Cancer Epidemiol. Biomarkers Prev., September 1, 1999; 8(9): 815 - 823. [Abstract] [Full Text]
|
|